
Fredun Pharmaceuticals Ltd. (FREDUN) 52 Week High Streak: Second Straight Session Near One-Year Peak
Updated: 19 Nov 2026 • 9:35 am
Posted by:

Fredun Pharmaceuticals Ltd. 52 Week High Streak has now stayed within 2% of its one-year peak for its second straight session, with the stock moving 5.46% across the streak. As of 19 November 2026 at 9:22 AM IST, the share price was at Rs 1,659.50 after touching Rs 1,680.65 during the morning trade. The latest Univest data confirms the repeated-high pattern, but it does not establish a company-specific catalyst for the continued move.
The stock previously traded at Rs 1,634.25, opened at Rs 1,645.10 and moved as low as Rs 1,645.10 before recovering through the morning range. Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 2,694.87 crore, so the current read is not just about a single-day move; it is about a repeated test near the same high zone across consecutive sessions, which makes the pattern more relevant than an isolated intraday print.
Fredun Pharmaceuticals Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,659.5 |
| Previous Close | Rs 1,634.25 |
| Today's Move | +Rs 25.25 (+1.55%) |
| Open | Rs 1,645.1 |
| High | Rs 1,680.65 |
| Low | Rs 1,645.1 |
| Market Capitalisation | Rs 2,694.87 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,659.5 versus the previous close of Rs 1,634.25, a rise of 1.55%. The stock opened at Rs 1,645.1, reached a high of Rs 1,680.65 and touched a low of Rs 1,645.1.
Fredun Pharmaceuticals Ltd. was trading at Rs 1,659.50, higher by Rs 25.25 or 1.55% versus the previous close of Rs 1,634.25. The stock opened at Rs 1,645.10 and touched an intraday high of Rs 1,680.65, while the low of the morning trade was also Rs 1,645.10. That places the price in the upper part of the range and keeps the stock near its yearly peak as the market watches the next move. Market capitalisation stood at Rs 2,694.87 crore, which helps frame the stock’s size within the healthcare universe.
For readers tracking Fredun Pharmaceuticals Ltd. share price today, the important point is not only the rupee change but the way the stock has remained near its 52-week high for a second straight session. The move has kept the name in the group of 52 Week High Stocks without turning it into a single-session event. That makes the present phase more useful for Fredun Pharmaceuticals Ltd. stock news readers who want to understand whether the current level is being sustained rather than merely touched once.
What the Repeated 52-Week Highs Show
The repeated near-high pattern shows that Fredun Pharmaceuticals Ltd. has remained close to its one-year peak across back-to-back sessions, with a cumulative gain of 5.46% during the streak. That is the clearest multi-session signal in the latest Fredun Pharmaceuticals Ltd. stock analysis: the market has kept the share price near the same elevated zone rather than letting it drift away after the first push. The latest Univest data confirms the price pattern, but it does not identify a company-specific reason for the continued strength.
For investors, that means the focus shifts from a one-off breakout story to the persistence of the move. In practical terms, a repeated 52-week high sequence can keep a stock on the radar of traders and long-term market watchers alike, but the article should not turn that pattern into a claim about cause. The better reading is that Fredun Pharmaceuticals Ltd. 52 Week High Streak is still developing, and the latest Univest figures only show price behaviour around the yearly high, not the reason behind it.
Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,694.87 crore |
| P/E Ratio | 52.84x |
| P/B Ratio | 8.08x |
| ROE | 16.09% |
| ROCE | 21.34% |
| EPS | Rs 30.93 |
| Book Value Per Share | Rs 202.35 |
| Dividend Yield | 0.01% |
Fredun Pharmaceuticals Ltd. (FREDUN) fundamental metrics show P/E 52.84x, P/B 8.08x, ROE 16.09%, ROCE 21.34%. These figures provide context only and are not a buy or sell signal.
Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 2,694.87 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 52.84x, P/B at 8.08x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.09% and ROCE of 21.34%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 30.93, book value per share of Rs 202.35, dividend yield of 0.01%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.53x, median ROE of 10.98%, median ROCE of 12.76%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 52.84x |
| Benchmark Median P/E | 26.53x |
| Benchmark Average P/E | 50.96x |
| Benchmark P/E Range | 0x to 1,378.1x |
| Company P/B Ratio | 8.08x |
| Benchmark Median P/B | 2.78x |
| Company ROE | 16.09% |
| Benchmark Median ROE | 10.98% |
| Company ROCE | 21.34% |
| Benchmark Median ROCE | 12.76% |
| Company Market Capitalisation | Rs 2,694.87 crore |
| Benchmark Median Market Cap | Rs 789.38 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 52.84x, which is above the benchmark median of 26.53x, a difference of +99.17%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 16.09%, which is above the benchmark median of 10.98%, a difference of +46.54%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 21.34%, which is above the benchmark median of 12.76%, a difference of +67.24%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Hikal Ltd. | HIKAL | 2,687.34 | 0 | 2.33 | -3.97 | -0.83 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,938.02 | 35.52 | 1.98 | 3.47 | 4 |
| Advanced Enzyme Technologies Ltd. | ADVENZYMES | 3,100.7 | 18.03 | 1.93 | 11.43 | 15.27 |
| Sakar Healthcare Ltd. | SAKAR | 2,309.43 | 52.41 | 6.49 | 10.04 | 12.52 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 3,213.55 | 85 | 2.19 | -0.63 | 4.61 |
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 52.84x compared with the displayed peer median of 35.52x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 16.09% compares with a peer median of 3.47% across the companies shown in the table. ROCE stood at 21.34% versus the displayed peer median of 4.61%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 2,694.87 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Fredun Pharmaceuticals Ltd.
- The stock has traded within 2% of its 52-week high for a second straight session.
- The cumulative move across the streak stands at 5.46%.
- The share price was Rs 1,659.50 as of 19 November 2026 at 9:22 AM IST.
- Valuation remains above the industry median on both P/E and P/B.
- ROE and ROCE are both above the industry medians in the latest comparison set.
About Fredun Pharmaceuticals Ltd.
Fredun Pharmaceuticals Ltd. is part of the Pharmaceuticals & Drugs industry in the Healthcare sector. The latest Univest figures place the company at a market capitalisation of Rs 2,694.87 crore, with valuation and return ratios that stand above the middle of its industry comparison set. For investors following Fredun Pharmaceuticals Ltd. stock performance, the company combines a repeated-high price pattern with a business profile that the market is currently pricing at a premium.
The stock is listed on NSE and BSE under the symbol FREDUN. Its latest share price position near the yearly high keeps it among the names attracting attention in the healthcare pack, while the company’s profitability ratios and EPS provide the fundamental backdrop that market readers usually track alongside price movement.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does Fredun Pharmaceuticals Ltd. 52 Week High Streak mean?
Ans. It means Fredun Pharmaceuticals Ltd. has traded within 2% of its 52-week high for consecutive sessions. In this case, the pattern has continued for a second straight session, which keeps the stock near its yearly peak rather than at a one-day spike.
How long has Fredun Pharmaceuticals Ltd. stayed near its yearly high?
Ans. According to the latest Univest data, the stock has stayed within 2% of its 52-week high for two consecutive sessions. That is why the current event is described as a second straight session near the yearly high.
What is the cumulative move across the streak?
Ans. The cumulative move across the streak is 5.46%. This figure is more useful than a single-day change because it captures how the stock has behaved across the full repeated-high pattern.
What is Fredun Pharmaceuticals Ltd. trading at right now?
Ans. As of 19 November 2026 at 9:22 AM IST, Fredun Pharmaceuticals Ltd. was trading at Rs 1,659.50. The stock was higher than the previous close of Rs 1,634.25 and remained near the top of the morning range.
Did the latest data confirm a company-specific catalyst?
Ans. No. The latest Univest data confirms the repeated price pattern near the 52-week high, but it does not establish a company-specific reason for the move. Readers should treat the pattern as a market fact, not a stated cause.
How does Fredun Pharmaceuticals Ltd. compare with its sector on valuation?
Ans. The company’s P/E of 52.84 is above the industry median of 26.53, and its P/B of 8.08 is above the industry median of 2.78. That places the stock at a premium to the middle of the healthcare industry comparison set.
What fundamental ratios stand out for Fredun Pharmaceuticals Ltd.?
Ans. ROE of 16.09% and ROCE of 21.34% stand out because both are above the industry medians in the comparison set. EPS is Rs 30.93 and book value is Rs 202.35, which gives readers a quick view of the company’s earnings and asset base.
What should investors monitor next?
Ans. Investors should watch whether the stock keeps holding near the same elevated price zone and how the valuation compares with peers over time. The next read will come from whether the repeated near-high pattern continues, not from a single intraday print.
Track Fredun Pharmaceuticals Ltd. (FREDUN) Share Price on Univest
Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Recent Articles

Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
18 November 2026

V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
18 November 2026

Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
18 November 2026

Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
Mahanadi Coalfields IPO Opens 19 November: Rs 129 to Rs 136 Price Band, Rs 8,981 Crore Offer for Sale and a Coal India Unit Valued at About 8.4 Times Earnings

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





